Replies to post #398421 on Amarin Corp Plc (AMRN)

[oneragman]

Chrome, I believe it's highly unlikely Denner fires any management right away even if he took over the entire board. The question is why doesn't AMRN management want him on the board at all? Don't they want to sell the company? Get the most value? They can't argue Denner would add no value. That's just bullshit. So what? It has to be the direction he would want to go will not be the same as where they do. I know where he wants to go. I don't really know where management does. The fact is their credibility is destroyed by their own actions. I don't trust them to do what is best for shareholders. Others talk about management and their plan. What plan? The fact is they don't have a plan. One is only ever vaguely communicated and then dropped to go in a different direction. As an example...what have they done about the inventory? This problem is years old and vaguely addressed like every other issue they have. So we can't afford to run a trial comparing V to gV, but we can have hundreds of millions in excess inventory? This company is run so poorly and has got away with it because of a big dilution and one hell of a drug, but the day of reckoning is coming unless we have a radical change from our present course. At the least, Denner having board seats should keep us being diluted into oblivion. They will do that in the next 18 months on the current trajectory because they won't have a choice.

[Whalatane]

Chromo. with all due respect to your biotech / science background ....do U understand the business risks here ?
This is going to be a half glass full post ...not intended as FUD altho some here will definitely read it that way .
We have had a fantastic run up recently due to better then expected cash on hand numbers and Dr Denners aggressive moves .
Your average costs as per your previous posts is $5.24 .
Any thought of selling some here to reduce your exposure ?

So the risks going forward that no one wants to discuss .
1) IF AMRN / Kaiser have stopped dispensing Vascepa in the MITIGATE trial , theres no 2 yr CV data to compare / support the R-IT numbers in the US population .
Therefore theres no additional clinical trial data to persuade Germany to lift its evidence of benefit rating from 11b ( 2b )
2) Without the additional clinical data France , Italy and Spain may follow Germany and decide for now not to provide reimbursement ...or if they do ...only for the very high risk , secondary prevention R-IT profile patients . So minimal sales
3) Sales in the UK are likely to be minimal
4) Script numbers start declining again in the US as more formularies drop coverage ...or simply raise the tier rating forcing higher copays for Brand Vascepa .
5) When U are running a business you can only cut / down size so much . AMRN may have done as much as they can in this area in the US ..or be close to it.
6) As poster oneragman mentioned ...risk of dilution . Reduced sales in the US , less room for cost cutting , minimal sales in the UK..... spells eventual dilution
7). Theres a real chance IMHO that no BP is interested in this Co .

Oh by the way ....For those who think China is going to bail U out ....chk out their negotiations for Paxlovid .
Chromo ...appreciate your posts .
Good luck with whatever U decide to do

Kiwi

[Bolio98]

i am still hopeful that they can reach an agreement with generics to let Amarim grow the market and then have generics come in a few years

That ship sailed a long time ago and I give that a 0% chance of happening, not that it wouldn't be a good idea.